Hemab Therapeutics Holdings, Inc. Increase (Decrease) in Accounts Payable
Hemab Therapeutics Holdings, Inc. (COAG) reported Increase (Decrease) in Accounts Payable of $498.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- Hemab Therapeutics Holdings, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $550.00K.
- Hemab Therapeutics Holdings, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$52.00K, a 101.80% decline year-over-year.
- Hemab Therapeutics Holdings, Inc. increase (decrease) in accounts payable for the quarter ending 2025-06-30 was -$2.32M.
- Hemab Therapeutics Holdings, Inc. increase (decrease) in accounts payable for the quarter ending 2025-03-31 was $2.88M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month |
|---|---|---|
| 2026-06-30 | $550.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $498.00K 10-Q · filed 2026-08-11 |
| 2026-03-31 | -$52.00K 10-Q · filed 2026-05-21 | |
| 2025-06-30 | -$2.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $564.00K 10-Q · filed 2026-08-11 |
| 2025-03-31 | $2.88M 10-Q · filed 2026-05-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |